Roche Group Member Genentech's Gazyva Shows Results In Lupus Nephritis Study, Could Delay Kidney Disease
Roche Group Member Genentech's Gazyva Shows Results In Lupus Nephritis Study, Could Delay Kidney Disease
羅氏集團成員基因泰克的Gazyva在狼瘡性腎炎研究中顯示出結果，可能延遲腎臟疾病。
Genentech, a member of the Roche Group ((SIX: RO, ROG, OTCQX:RHHBY), announced today positive topline results from the Phase III REGENCY study of Gazyva (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated with Gazyva plus standard therapy (mycophenolate mofetil and glucocorticoids) achieved a complete renal response (CRR) at 76 weeks compared to those treated with standard therapy alone. Safety was in line with the well-characterized profile of Gazyva. No new safety signals were identified.
羅氏集團成員基因泰克（Roche Group）（SIX: RO, ROG, OTCQX:RHHBY）今天宣佈，Gazyva（obinutuzumab）在進行中的第III期REGENCY研究中的上線結果積極，該研究針對患有活動性狼瘡性腎炎的患者。在該研究中，接受Gazyva聯合標準療法（麥考酚酯酶和糖皮質激素）治療的患者在76周時完成腎臟反應（CRR）的比例較接受單獨標準療法治療的患者更高。安全性與Gazyva的良好特性一致。未發現新的安全信號。
"Gazyva achieved a robust complete renal response rate in lupus nephritis, which is associated with long-term...
"Gazyva在狼瘡性腎炎中取得了...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間